Department of Gastroenterology and Hepatology, Hillel Yaffe Medical Center, Faculty of Medicine, Technion University, Hadera, Israel.
Department of Liver Diseases, Sheba Medical Center, Sackler Faculty of Medicine, University of Tel Aviv, Ramat Gan, Israel.
Minerva Med. 2023 Oct;114(5):658-666. doi: 10.23736/S0026-4806.23.08428-8. Epub 2023 Mar 13.
Concomitant Diabetes mellitus (DM) is commonly recognized in patients with chronic hepatitis B (CHB) infection, although its impact on liver-related outcomes remains controversial. We aimed to evaluate the effect of DM on the course, management and outcome of patients with CHB.
We performed a large retrospective cohort study utilizing the Leumit-Health-Service (LHS) database. We reviewed electronic reports of 692106 LHS members from different ethnicities and districts in Israel from 2000-2019 and included patients with CHB diagnosis based on ICD-9-CM codes and supportive serology results. These were divided into two cohorts of patients with CHB and DM (CHD-DM) (N.=252) and those with CHB without DM (N.=964). Clinical parameters, treatment figures and patients' outcomes were compared and multiple regression models and Cox regression analysis were performed to investigate the association between DM and cirrhosis/HCC risk in CHB patients.
CHD-DM patients were significantly older (49.2±10.9 vs. 37.9±14, P<0.001), and had higher rates of obesity (BMI>30) and NAFLD (47.2% vs. 23.1%, and 27% vs. 12.6%, P<0.001, respectively). Both groups had a predominance of inactive carrier (HBeAg negative infection) state, but the HBeAg seroconversion rate was significantly lower in the CHB-DM group (25% vs. 45.7%; P<0.01). Multivariable Cox regression analysis showed that DM was independently associated with increased cirrhosis risk (HR 2.63; P=0.002). Older age, advanced fibrosis and DM were associated with HCC, but DM did not reach significance (HR 1.4; P=0.12) possibly due to the small number of HCC cases.
Concomitant DM in CHB patients was significantly and independently associated with cirrhosis and possibly with increased risk of HCC.
慢性乙型肝炎(CHB)感染患者常伴有糖尿病(DM),但其对肝脏相关结局的影响仍存在争议。我们旨在评估 DM 对 CHB 患者病程、管理和结局的影响。
我们进行了一项大型回顾性队列研究,利用 Leumit-Health-Service(LHS)数据库。我们查阅了 2000 年至 2019 年间来自以色列不同族裔和地区的 692106 名 LHS 成员的电子报告,并根据 ICD-9-CM 代码和支持性血清学结果纳入 CHB 诊断患者。这些患者被分为 CHB 伴 DM(CHD-DM)(n=252)和 CHB 不伴 DM(n=964)两组。比较了两组患者的临床参数、治疗数据和患者结局,并进行了多变量回归模型和 Cox 回归分析,以探讨 DM 与 CHB 患者肝硬化/肝细胞癌(HCC)风险之间的关系。
CHD-DM 患者明显更年长(49.2±10.9 岁 vs. 37.9±14 岁,P<0.001),肥胖(BMI>30)和非酒精性脂肪性肝病(NAFLD)的发生率更高(分别为 47.2% vs. 23.1%和 27% vs. 12.6%,均 P<0.001)。两组患者均以非活动型携带者(HBeAg 阴性感染)状态为主,但 CHB-DM 组的 HBeAg 血清学转换率明显较低(25% vs. 45.7%;P<0.01)。多变量 Cox 回归分析显示,DM 与肝硬化风险增加独立相关(HR 2.63;P=0.002)。年龄较大、晚期纤维化和 DM 与 HCC 相关,但 DM 未达到显著水平(HR 1.4;P=0.12),可能是因为 HCC 病例数较少。
CHB 患者合并 DM 与肝硬化显著且独立相关,可能与 HCC 风险增加相关。